Correction of metabolic disorders in patients co-infected with HIV/HCV
DOI:
https://doi.org/10.15587/2313-8416.2015.51664Keywords:
Co-infection HIV\HCV, metabolic disorders, cytokines, lipid metabolism, correction, efficiency, phosphoglivAbstract
There was studied an effectiveness of phosphogliv in correction of metabolic disorders in patients co-infected with HIV\HCV.
Methods: There were examined 40 patients co-infected with HIV|HCV separated into two groups. 1 group included 22 patients co-infected with HIV\HCV who received phosphogliv, 2 capsules 3 times a day during 6 month. The second group included 18 patients who received simvastatin, 10mg\kg\day during 6 month.
Results: Phosphogliv therapy leads to reliable decrease of ІL-8, ІL-10, ІL-1β, ІL-6, TNF-α and increase of ІL-2. In patients of the 1 group it were registered the reliable decrease of potassium and also increase of sodium, calcium, magnesium, zinc, copper and iron after treatment. Under an influence of phosphogliv it was observed reliable decrease of the level of insulin resistance, glycated hemoglobin, insulin, glucose and uric acid.
Phosphogliv favors reliably more intense influence on cytokine (р<0,05), mineral (р<0,001) and carbohydrate metabolism (р<0,05) compared to simvastatin. Both preparations favor an intense positive dynamics of the lipid spectrum parameters but in patients who received simvastamin it was registered the more significant increase of HDL and therapy with phosphogliv leads to reliably more significant decrease of LDL (р<0,05) and VLDL(р<0,01).
Conclusions: Phosphogliv is very effective in correction of metabolic disorders in patients co-infected with HIV\HCV it favors the reliable positive dynamics of parameters of cytokine, mineral, lipid and carbohydrate types of metabolism. Phosphogliv has the more intense effect on cytokine, mineral and carbohydrate metabolism compared to simvastatin
References
Maksimov, S. L. (2010). The clinical course, outcomes and treatment of viral hepatitis in patients with HIV infection. Moscow, 46.
Fedorchenko, S. V. (2010). Chronic HCV-infection. Kiev: Meditsina, 271.
Jacobson, D. L., Tang, A. M., Spiegelman, D., Thomas, A. M., Skinner, S., Gorbach, S. L., Wanke, C. (2006). Incidence of Metabolic Syndrome in a Cohort of HIV-Infected Adults and Prevalence Relative to the US Population (National Health and Nutrition Examination Survey). JAIDS Journal of Acquired Immune Deficiency Syndromes, 43 (4), 458–466. doi: 10.1097/01.qai.0000243093.34652.41
Shoelson, S. E., Lee J., Goldfine A. B. (2006). Inflammation and insulin resistance. Journal of Clinical Investigation, 116 (7), 1793–1801. doi: 10.1172/jci29069
Iurko, Е. V. (2014). Characteristic of cytokine metabolism in patients with HIV/HCV co-infection. International medical journal, 4, 72–74.
Iurko, Е. V. (2014). Assessment of mineral metabolism metabolic disorders in HIV-infected patients, patients with chronic hepatitis C and co-infection HIV/HCV. Saratov Journal of Madical Scientific Research, 10 (4), 617–622.
Kozko, V. M, Iurko, K. V, Solomennyk, G. О. (2014). The state of lipid metabolism indices in HIV-infected persons, patients with chronic hepatitis C and co-infection HIV/HCV. Gepatologia, 4 (26), 33–39.
Kozko, V. M, Iurko, K. V, Solomennyk, G. О, Antsyferova, N. V. (2015). Status indicators of carbohydrate metabolism in patients co-infected with HIV/HCV. Gepatologia, 1, 72–80.
Chernobrovkina, T. Ya. (2006). The efficacy of phosphogliv in hepatitis C. International medical journal, 1, 94–98.
Mayevskaya, M. V. (2011). Preliminary results of open comparative randomized study PHG-M3/R01-09 "Orion" on the drug "Phosphogliv" in combination therapy in patients with chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 21 (4), 52–59.
Zosimov, A. N. (2000). System analysis in medicine. Kharkov: Tornado, 82.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Катерина Володимирівна Юрко, Володимир Миколайович Козько, Ганна Олегівна Соломенник
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
